Back to mobile site

Goldman Sachs Reiterates Neutral Rating on Annexon Biosciences (ANNX)

August 6, 2026 4:16 PM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $7.00 price target on Annexon Biosciences (NASDAQ: ANNX)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login